Read more

November 24, 2020
1 min read
Save

Development of treatment cascade feasible for HIV/HCV coinfection

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers developed a statewide hepatitis C treatment cascade for people coinfected with HIV using statewide surveillance data, according to a presenter at IDWeek.

“We took on this project due to the fairly high prevalence of HCV/HIV coinfection in the United States as well as gaps in current HCV treatment cascade research, which focuses on monoinfected individuals as well as being developed using data sources other than public health surveillance,” Maximilian D. Wegener, MPH, said during a virtual poster presentation.

For the project, Wegener and colleagues used two surveillance databases located at the Connecticut Department of Public Health, including the CT Electronic Disease Surveillance System (CTEDSS) for HCV and the electronic HIV/AIDS Reporting System (eHARS) for HIV. To identify coinfection, researchers matched the two databases using a validated matching algorithm.

Investigators evaluated two HCV surveillance timelines, including a cumulative timeframe that included all CTEDSS entries from 1994 through 2020 and an abbreviated timeframe that included all CTEDSS entries ever with labs from 2016 through 2020.

The researchers assessed HCV labs using a standardized surveillance case definition to determine cascade status after exclusion of those who were deceased, out of state, not infected with HCV or had unknown HCV infection status.

In the analysis of the abbreviated cascade, the sustained virologic response (SVR) rate of 68.6%. The SVR rate differed for the cumulative timeframe (36.5%), but the abbreviated cascade timeframe likely better represents the current coinfected population, Wegener said.

Additional analysis also showed that those most likely to achieve SVR were baby boomers and those with low or undetectable HIV viral loads.

“This will hopefully give future projects insight on who to target to improve SVR rates for HCV/HIV coinfected populations,” Wegener said.